Related Experiment Video

Updated: May 18, 2026

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

Do patients with heart failure benefit from coronary artery bypass grafting?

Edwin C McGee1, Patrick M McCarthy

  • 1Division of Cardiac Surgery, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611-2968, USA. emcgee@nmh.org

Current Opinion in Cardiology
|October 4, 2012
PubMed

Insights

Coronary artery bypass grafting (CABG) is beneficial for select patients with ischemic cardiomyopathy and heart failure. This review confirms CABG

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Heart Failure Management

Background:

  • Ischemic cardiomyopathy and congestive heart failure significantly impact patient prognosis.
  • Coronary artery bypass grafting (CABG) is a cornerstone therapy for advanced coronary artery disease.

Purpose of the Study:

  • To evaluate the appropriateness and benefits of CABG in patients presenting with ischemic cardiomyopathy and concurrent congestive heart failure.
  • To critically analyze the role of CABG in managing heart failure secondary to coronary artery disease.

Main Methods:

  • Review of existing literature and critical analysis of key clinical trials, including the Surgical Treatment of Ischemic Heart Failure (STICH) trial.
  • Assessment of safety and efficacy data for CABG in the specified patient population.

Main Results:

  • CABG is established as the gold standard for advanced multivessel and left main coronary artery disease.
  • The STICH trial provides evidence supporting the benefits of CABG for patients with ischemic cardiomyopathy.
  • CABG demonstrates safety and efficacy when applied to carefully selected patients with heart failure.

Conclusions:

  • CABG is a safe and effective treatment option for appropriately selected patients with ischemic cardiomyopathy and heart failure.
  • The benefits of CABG extend to improving outcomes in patients with heart failure due to coronary artery disease.
Abstract

More Related Videos

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft05:25

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft

Published on: September 15, 2023

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...